Mostrar el registro sencillo del ítem
Calidad de vida en paciente sometidos a trasplante de progenitores hematopoyéticos. Estudio de cohorte retrospectiva
dc.contributor.advisor | Sossa Melo, Claudia Lucía | spa |
dc.contributor.advisor | Ochoa Vera, Miguel Enrique | spa |
dc.contributor.author | Pinto Saavedra, Oscar Mariano | spa |
dc.contributor.author | Serrano Báez, Gustavo Adolfo | spa |
dc.date.accessioned | 2020-06-26T19:59:56Z | |
dc.date.available | 2020-06-26T19:59:56Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12749/1743 | |
dc.description.abstract | Antecedentes: Con el aumento de la sobrevida a largo plazo en los pacientes trasplantados de médula ósea, ha tomado importancia la valoración de la calidad de vida relacionada con salud (CVRS), por lo que surge un fuerte interés en estudiar el impacto de esta en los supervivientes. El compromiso de la CVRS puede verse afectado debido, a la toxicidad que implica el procedimiento, secundario a la intensidad de la quimioterapia, de la radioterapia, las secuelas asociadas a la enfermedad de injerto contra el huésped (EICH) y las complicaciones de los tratamientos asociados. Métodos: Mediante un estudio descriptico analítico tipo cohorte retrospectivo, se evaluó la CVRS en 49 pacientes trasplantados en la unidad de trasplante de médula ósea de la FOSCAL, mediante la aplicación del cuestionario EORCT QLQ C 30, en un periodo de tiempo comprendido entre noviembre del año 2014 y marzo del año 2016. Resultados: Durante el periodo de evaluación (6 meses), se observó un deterioro en la calidad de vida predominantemente en la escala de funcionalidad durante el primer mes, independiente del tipo de trasplante realizado y la cual mejora hacia el tercer mes del trasplante. En el trasplante de precursores hematopoyéticos (TPH) autólogo, se documentó una disminución de la CVRS, luego del tercer mes. Al comparar por tipo de trasplante se documentó un empeoramiento de predominio en el grupo de TPH autólogo en comparación con el TPH alogénico; al mes de seguimiento en funcionalidad de rol (RR: 2); a los tres meses la diferencia se documentó en funcionalidad social y dolor en contra del TPH autólogo (RR: 4,1 y 1,85 respectivamente) a los seis meses no hubo diferencias estadísticamente significativas entre los dos grupos. Se realizó subanálisis midiendo incidencia de deterioro entre los dos tipos de trasplante pero excluyendo el grupo de acondicionamiento no mielo ablativo documentando diferencias significativas al mes en deterioro significativo en salud general (RR 3.08, IC 95%, 1,13--8.45), función física (RR 1.98, IC 95%, 1,12--3,52), función de rol (RR 2.7, IC 95%, 1,58--4.6), fatiga (RR 3.85, IC 95%, 1,56--9.56), náuseas y vómito (RR 2.89, IC 95%, 1,28--6.53) y en menos medida dolor (RR 2.64, IC 95%, 1,01--6.92). En el tercer mes se evidenciaron cambios en función emocional (RR 4.63, IC 95%, 1,13--18.87) y función social (RR 6.17, IC 95%, 1.7--22.34) y a los seis meses en salud general (RR 2.31, IC 95%, 1.09--4.92).Conclusiones: Se determinó que durante el primer trimestre es donde el procedimiento de TPH, impacta más negativamente en la CVRS de los pacientes, con una mejoría significativa después del tercer mes; Alcanzado un equilibrio al sexto mes; si bien no hubo diferencias en puntajes establecidos por el EORCT QLQ C 30; de más de 30 puntos, si se documenta una clara asociación con la mejoría en la calidad de vida en los pacientes sometidos a TPH. Por otro lado se evidenció que al trasplante autólogo tiene mayor deterioro por impacto en la calidad de vida que los alogénicos. Cuando se realizó el subanálisis midiendo incidencia de deterioro al mes, tres y seis meses, se evidencio mayor deterioro en algunos aspectos, en los pacientes con trasplante alogénico sobre el trasplante autólogo, sin ninguna diferencia del autólogo sobre el alogénico. | spa |
dc.description.tableofcontents | INTRODUCCIÓN……………………………………………………………………10 1. OBJETIVO GENERAL…………………………………………………………..11 1.1 Objetivos Específicos………………………………………………………11 2. PLANTEAMIENTO DEL PROBLEMA…………………………………………12 3. MARCO TEÓRICO Y ESTADO DEL ARTE…………………………………..12 4. METODOLOGIA ………………………………………………………………….21 4.1 Diseño…….……………………………………………………………………21 4.2 Universo…….…………………………………………………………………21 4.3 Población Objeto……….……………………………………………………21 4.4 Muestra………………………………………………………………………..21 4.5 Criterios de inclusión y exclusión……………………………………….21 4.6 Variables……………………………………………………………………...22 4.7 manejo de la información y obtención de la información…………..25 4.8 Plan de Análisis……………………………………………………………..26 5. CONSIDERACIONES ÉTICAS…………………………………………………27 6. CRONOGRAMA…………………………………………………………………27 7. RESULTADOS ESPERADOS…………………………………………………28 8. CONFORMACIÓN Y TRAYECTORIA EL GRUPO DE INVESTIGACIÓN..28 9. RESULTADOS…………………………………………………………………...29 10. DISCUSION……………………………………………………………………..66 11. CONCLUSIONES………………………………………………………………68 12. BIBLIOGRAFIA………………………………………………………………...69 13. LISTA DE ANEXOS……………………………………………………………74 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | * |
dc.title | Calidad de vida en paciente sometidos a trasplante de progenitores hematopoyéticos. Estudio de cohorte retrospectiva | spa |
dc.title.translated | Quality of life in patient undergoing hematopoietic stem cell transplantation. Retrospective cohort study | eng |
dc.degree.name | Especialista en Medicina Interna | spa |
dc.coverage | Bucaramanga (Santander, Colombia) | spa |
dc.publisher.grantor | Universidad Autónoma de Bucaramanga UNAB | spa |
dc.rights.local | Abierto (Texto Completo) | spa |
dc.publisher.faculty | Facultad Ciencias de la Salud | spa |
dc.publisher.program | Especialización en Medicina Interna | spa |
dc.description.degreelevel | Especialización | spa |
dc.type.driver | info:eu-repo/semantics/masterThesis | |
dc.type.local | Tesis | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_bdcc | |
dc.subject.keywords | Quality of life | eng |
dc.subject.keywords | Hematopoiesis | eng |
dc.subject.keywords | Stem cells | eng |
dc.subject.keywords | Transplant | eng |
dc.subject.keywords | Medicine | eng |
dc.subject.keywords | Internal medicine | eng |
dc.subject.keywords | Investigations | eng |
dc.subject.keywords | Complications | eng |
dc.subject.keywords | Patients | eng |
dc.subject.keywords | Prevention and control | eng |
dc.subject.keywords | Bone marrow transplant | eng |
dc.subject.keywords | Symptom | eng |
dc.subject.keywords | Autologous transplant | eng |
dc.subject.keywords | Allogeneic transplant | eng |
dc.identifier.instname | instname:Universidad Autónoma de Bucaramanga - UNAB | spa |
dc.identifier.reponame | reponame:Repositorio Institucional UNAB | spa |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.relation.references | Pinto Saavedra, Oscar Mariano, Serrano Báez, Gustavo Adolfo (2016). Calidad de vida en paciente sometidos a trasplante de progenitores hematopoyéticos. Bucaramanga (Santander, Colombia) : Universidad Autónoma de Bucaramanga UNAB | spa |
dc.relation.references | 1. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med. 2006;354 (17):1813 26. | spa |
dc.relation.references | 2. Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovó A, Buser A, Stern M, Tichelli A, Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly. 142 (2012), 1-15. | spa |
dc.relation.references | 3. The NCCN GUIDELINE Practice Guidelines in Oncology—v.2.2011. Copyright 2011 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed [August 01, 2011]. To view the most recent and complete version of the guideline, go online to www.nccn.org. 2011. | spa |
dc.relation.references | 4. Horan JT, Logan BR, Agovi-Johnson MA, et al: Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation:How much progress has been made? J Clin Oncol 29:805, 2011. | spa |
dc.relation.references | 5. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011 Feb;25(1):101-16. Doi: 10.1016/j.hoc.2010.11.008. | spa |
dc.relation.references | 6. 43.Gragert L, Maiers M, Williams E, et al: Modeling effective patient-donor matching for hematopoietic transplantation in United States populations. Human Immunol 71:S114, 2010. | spa |
dc.relation.references | 7. Anasetti C, Logan B, Lee SJ, et al: Increased Incidence of Chronic Graft- Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood 118; Ash Annual Meeting Abstracts: Abstract 1, 2011. | spa |
dc.relation.references | 8. D Sirinoglu, Tekgunduz E, Altuntas F. What Is the Most Appropriate Source for Hematopoietic Stem Cell Transplantation? Peripheral Stem Cell/Bone Marrow/Cord Blood. Bone Marrow Res. 2012;2012:834040. Doi: 10.1155/2012/834040. Epub 2012 Sep 27. | spa |
dc.relation.references | 9. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, De Witte T, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, Ruiz de Elvira C, Falkenburg F, Sureda A, Madrigal A and for the European Group for Blood and Marrow Transplantation (EBMT) The EBMT activity survey: 1990-2010. Bone Marrow transplantation 47, 906-923 (July 2012). | spa |
dc.relation.references | 10. Eckrich M, Pasquini M. Hematopoietic cell transplantation in Latin America. Hematology 2012; 17 Suppl 1: S189-91. | spa |
dc.relation.references | 11. Hjermstad MJ, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation. A review of the liteterature. Eur J Cancer. 1995;31 A(2):163-73. | spa |
dc.relation.references | 12. Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27:S148. | spa |
dc.relation.references | 13. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69:1155. | spa |
dc.relation.references | 14. Cella DF. Measuring quality of life in palliative care. Semin Oncol 1995; 22:73. | spa |
dc.relation.references | 15. Etcheld M, Van Elderen T, Van Der Kamp L, Modeling Predictors of quality of life after coronary angioplasty. Annals of Behavioral Medicine 2003; 26: 49-60. | spa |
dc.relation.references | 16. Awad A, Voruganti L, Heselgrave R, A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual Life Res 1997; 6: 21-6. | spa |
dc.relation.references | 17. O’Boyle C. The Schedule for the evaluation of individual Quality of life (SEIQoL). Internacional Journal of Mental Health 1994; 23 (3): 3-23. | spa |
dc.relation.references | 18. WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL). Position Paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-9. | spa |
dc.relation.references | 19. Urzúa A. Calidad de vida relacionado con la salud: Elementos conceptuales. Rev Med Chile 2010; 138: 358-365 | spa |
dc.relation.references | 20. Bakas T, McLennon S, Carpenter J, Buelow M, Otte J, Hanna K, Ellet M, Hadler K, Welch J. Systematic review of health-related quality of life models. Health and Quality of Life Outcomes 2012, 10:134 | spa |
dc.relation.references | 21. Peterman AH, Rothrock N, Cella D. Evaluation of health-related quality of life. Uptodate; 2014.[Acceso 4 de marzo del 2014]. Disponible en: http:www.uptodate.com/ | spa |
dc.relation.references | 22. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091. | spa |
dc.relation.references | 23. Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplantation (2012) 47, 473–482 | spa |
dc.relation.references | 24. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001. | spa |
dc.relation.references | 25. Sanchez R, Venegas M, Otero J, Sanchez O. Adaptación transcultural de dos escalas para medir la calidad de vida en pacientes con cáncer en Colombia: EORTC QLQ-C30 y QLQ-BR23. Rev Colomb Cancerol 2009;13(4):205-212 2 | spa |
dc.relation.references | 26. Carreras E, Brunet S, Ortega JJ, Roviera M, Sierra J. 2004. Manual de trasplante hematopoyético 2004. 4 Ed. Barcelona, Antares; Capitulo: compliaciones del TPH. | spa |
dc.relation.references | 27. Aaronson NK, Ahmedzai S, Bergmann B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365 376 | spa |
dc.relation.references | 28. Gratwohk A, Stern M, Brand R, et al. Risk score for outcome after allogenicematopoietic stem cell transplantation. Cancer 2009; 115: 4715--26 | spa |
dc.relation.references | 29. Fayers P. Quality of life research within the EORTC the EORTC QLQ C30. European Journal of Cancer 38 (2002) S125 S133 | spa |
dc.relation.references | 30. Bieri S, Roosnek E, Helg C, Verholen F, et al. Quality of life and social integration after allogeneic hematopoietic SCT. Bone Marrow Transplantation (2008) 42, 819 827. | spa |
dc.relation.references | 31. Article O. Frequent and long term follow up of health related quality of life following allogeneic haematopoietic stem cell transplantation. 2015; | spa |
dc.relation.references | 32. Wettergren L, Sprangers M, Bjo M. Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument. 2008;346(July 2007):338 46. | spa |
dc.contributor.cvlac | https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000898465;https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001425704 | * |
dc.contributor.cvlac | https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001692640 | * |
dc.contributor.googlescholar | https://scholar.google.es/citations?hl=es&user=DdZsdW4AAAAJ | * |
dc.contributor.orcid | https://orcid.org/0000-0002-4552-3388 | * |
dc.contributor.scopus | https://www.scopus.com/authid/detail.uri?authorId=36987156500;https://www.scopus.com/authid/detail.uri?authorId=57203553484 | * |
dc.contributor.researchgate | https://www.researchgate.net/profile/Miguel_Ochoa7;https://www.researchgate.net/profile/Claudia_Sossa?_sg=BvRoh6IvojFf2p-POYF__s50hoM8A_BUZv09EbDIIEubX8HzSQD8c55b5wN2DjEMJzlDAXO3X74Ci8Q | * |
dc.subject.lemb | Calidad de vida | spa |
dc.subject.lemb | Hematopoyesis | spa |
dc.subject.lemb | Células madre | spa |
dc.subject.lemb | Trasplante | spa |
dc.subject.lemb | Medicina | spa |
dc.subject.lemb | Medicina interna | spa |
dc.subject.lemb | Investigaciones | spa |
dc.subject.lemb | Complicaciones | spa |
dc.subject.lemb | Pacientes | spa |
dc.subject.lemb | Prevención y control | spa |
dc.description.abstractenglish | Background: With the increase in long-term survival in bone marrow transplant patients, the assessment of health-related quality of life (HRQOL) has become important, so there is a strong interest in studying the impact of this on survivors. The compromise of HRQOL may be affected due to the toxicity involved in the procedure, secondary to the intensity of chemotherapy, radiotherapy, the sequelae associated with graft-versus-host disease (GVHD), and the complications of treatments. associates. Methods: Through a descriptive analytical retrospective cohort study, HRQoL was evaluated in 49 transplant patients in the FOSCAL bone marrow transplant unit, by applying the EORCT QLQ C 30 questionnaire, in a period of time between November 2014 and March 2016. Results: During the evaluation period (6 months), a deterioration in the quality of life was observed, predominantly in the functionality scale during the first month, independent of the type of transplant performed and which improves towards the third month after transplantation. In autologous hematopoietic stem cell transplantation (HPT), a decrease in HRQL was documented, after the third month. When comparing by type of transplantation, a predominance worsening was documented in the autologous HSCT group compared to allogeneic HSCT; one month of follow-up in role functionality (RR: 2); At three months the difference was documented in social functionality and pain against autologous HSCT (RR: 4.1 and 1.85 respectively). At six months there were no statistically significant differences between the two groups. Subanalysis was performed measuring the incidence of deterioration between the two types of transplantation but excluding the non-myeloablative conditioning group, documenting significant differences at one month in significant deterioration in general health (RR 3.08, 95% CI, 1.13--8.45), function physical (RR 1.98, 95% CI, 1.12-3.52), role function (RR 2.7, 95% CI, 1.58-4.6), fatigue (RR 3.85, 95% CI, 1.56 --9.56), nausea and vomiting (RR 2.89, 95% CI, 1.28--6.53) and to a lesser extent pain (RR 2.64, 95% CI, 1.01--6.92). Changes in emotional function (RR 4.63, 95% CI, 1.13--18.87) and social function (RR 6.17, 95% CI, 1.7--22.34) and at six months in general health (RR 2.31, 95% CI, 1.09--4.92).Conclusions: It was determined that during the first trimester is where the HSCT procedure has the most negative impact on the patients' HRQoL, with a significant improvement after the third month; Balanced at the sixth month; although there were no differences in scores established by the EORCT QLQ C 30; of more than 30 points, if a clear association with an improvement in quality of life is documented in patients undergoing HSCT. On the other hand, it was evidenced that autologous transplantation has greater deterioration due to the impact on quality of life than allogeneic transplants. When the sub-analysis was performed measuring incidence of deterioration at one, three and six months, greater deterioration was evidenced in some aspects, in patients with allogeneic transplantation over autologous transplantation, with no difference between autologous and allogeneic. | eng |
dc.subject.proposal | Trasplante de médula ósea | |
dc.subject.proposal | Síntoma | |
dc.subject.proposal | Trasplante autólogo | |
dc.subject.proposal | Trasplante alogénico | |
dc.type.redcol | http://purl.org/redcol/resource_type/TM | |
dc.rights.creativecommons | Atribución-NoComercial-SinDerivadas 2.5 Colombia | * |
dc.contributor.researchgroup | Grupo de Investigaciones Clínicas | spa |
dc.coverage.campus | UNAB Campus Bucaramanga | spa |
dc.description.learningmodality | Modalidad Presencial | spa |